RxDoctor Payments Data

Nirmal Kumar Kumaradas Antonio, MD

Internal Medicine · Kingwood, TXNPI 1518186451

Payments from drug & device makers

$3,694in general payments, 2019–2025

Across 207 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$452
  • Merck$428
  • AbbVie$411
  • Bayer$347
  • AstraZeneca$260
  • Amgen$189
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$3,57697%
  • Education$1173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,694 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$37,916
Medicare patients
116
Services billed
523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$143,764
MounjaroTirzepatide75$97,214
EliquisApixaban81$74,270
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$44,993
JanuviaSitagliptin Phosphate39$39,698
JardianceEmpagliflozin32$33,205
VascepaIcosapent Ethyl24$21,632
Humalog Kwikpen U-200Insulin Lispro18$21,028
XareltoRivaroxaban27$19,883
Repatha SureclickEvolocumab22$14,559
MyrbetriqMirabegron11$14,400
LinzessLinaclotide17$12,991
Repatha SyringeEvolocumab23$12,907
GemtesaVibegron14$12,037
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen285$11,432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$164$143,764101 claims
Lilly USA, LLCMounjaro$159$97,21475 claims
PfizerEliquis$116$74,27081 claims
GSKTrelegy Ellipta, Breo Ellipta$452$50,53167 claims
MerckJanuvia, Lagevrio (Eua)$428$46,42456 claims
Boehringer IngelheimJardiance$34$33,20532 claims
Johnson & JohnsonXarelto$54$19,88327 claims
Astellas Pharma US IncMyrbetriq$143$14,40011 claims
AbbVieLinzess$411$12,99117 claims
AstraZenecaSymbicort$260$7,39321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →